Day One Biopharmaceuticals (NASDAQ:DAWN) CFO Charles York II Sells 4,062 Shares

Day One Biopharmaceuticals, Inc. (NASDAQ:DAWN) CFO Charles York II sold 4,062 shares of the business’s stock in a transaction that occurred on Monday, November 17th. The stock was sold at an average price of $8.91, for a total transaction of $36,192.42. Following the completion of the transaction, the chief financial officer owned 294,715 shares of the company’s stock, valued at $2,625,910.65. This trade represents a 1.36% decrease in their position. The transaction was disclosed in a legal filing with the Securities & Exchange Commission, which is available through this hyperlink.

Day One Biopharmaceuticals Stock Down 3.1%

Shares of DAWN stock opened at $8.57 on Wednesday. The firm has a market cap of $879.97 million, a price-to-earnings ratio of -5.64 and a beta of -1.25. Day One Biopharmaceuticals, Inc. has a 12 month low of $5.64 and a 12 month high of $14.46. The stock has a 50-day moving average price of $7.65 and a 200 day moving average price of $7.06.

Day One Biopharmaceuticals (NASDAQ:DAWN) last issued its earnings results on Tuesday, November 4th. The company reported ($0.19) earnings per share (EPS) for the quarter, beating the consensus estimate of ($0.28) by $0.09. Day One Biopharmaceuticals had a negative net margin of 113.53% and a negative return on equity of 32.05%. The company had revenue of $39.80 million for the quarter, compared to analyst estimates of $38.20 million. During the same quarter last year, the firm earned $0.38 EPS. The company’s revenue for the quarter was down 57.6% on a year-over-year basis. Sell-side analysts predict that Day One Biopharmaceuticals, Inc. will post -0.72 earnings per share for the current fiscal year.

Analysts Set New Price Targets

A number of analysts have commented on the stock. JPMorgan Chase & Co. lifted their target price on shares of Day One Biopharmaceuticals from $26.00 to $27.00 and gave the stock an “overweight” rating in a report on Friday, November 7th. Zacks Research raised Day One Biopharmaceuticals from a “hold” rating to a “strong-buy” rating in a research note on Monday, October 13th. Piper Sandler upped their price objective on Day One Biopharmaceuticals from $25.00 to $26.00 and gave the company an “overweight” rating in a report on Wednesday, November 5th. Needham & Company LLC reduced their target price on Day One Biopharmaceuticals from $18.00 to $16.00 and set a “buy” rating on the stock in a report on Wednesday, August 6th. Finally, Weiss Ratings reaffirmed a “sell (d-)” rating on shares of Day One Biopharmaceuticals in a research note on Thursday, October 30th. One analyst has rated the stock with a Strong Buy rating, seven have given a Buy rating and one has issued a Sell rating to the company. Based on data from MarketBeat.com, the company presently has an average rating of “Moderate Buy” and an average price target of $24.43.

Hedge Funds Weigh In On Day One Biopharmaceuticals

Institutional investors have recently modified their holdings of the business. Rubric Capital Management LP bought a new stake in Day One Biopharmaceuticals during the 3rd quarter worth approximately $23,808,000. Alyeska Investment Group L.P. boosted its holdings in shares of Day One Biopharmaceuticals by 61.6% in the first quarter. Alyeska Investment Group L.P. now owns 4,059,764 shares of the company’s stock valued at $32,194,000 after buying an additional 1,547,577 shares during the period. AIGH Capital Management LLC bought a new stake in shares of Day One Biopharmaceuticals during the third quarter worth $10,719,000. Mak Capital One LLC bought a new stake in shares of Day One Biopharmaceuticals during the third quarter worth $10,212,000. Finally, Balyasny Asset Management L.P. bought a new stake in Day One Biopharmaceuticals in the 3rd quarter valued at $9,758,000. Institutional investors own 87.95% of the company’s stock.

About Day One Biopharmaceuticals

Day One Biopharmaceuticals, Inc, a clinical-stage biopharmaceutical company, develops and commercializes targeted therapies for patients with genomically defined cancers. Its lead product candidate is tovorafenib, an oral brain-penetrant type II pan-rapidly accelerated fibrosarcoma kinase inhibitor that is in Phase II clinical trial for pediatric patients with relapsed/ refractory low-grade glioma.